Cryo-Cell Announces Corporate Relocation

December 6, 2004

Strategic Capital Investment in State-of-the-Art Facility Positions Cryo-Cell in the Market and Ahead of Emerging Regulation

Oldsmar, FL – December 6, 2004 - Cryo-Cell International, Inc. (OTC Bulletin Board Symbol: CCEL) (the “Company”), one of the world’s oldest and largest private cord blood banks, announced today the relocation of its corporate headquarters to a newly constructed, nearly 18,000 square-foot state-of-the-art current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. The highly secured, technologically advanced facility is located less than five miles from the Company’s previous site and is designed to support the expansive and growing base of Cryo-Cell clients over the next ten years. This formal announcement comes on the heels of record setting revenue in the third quarter ended August 31, 2004 for the Company, which was established in 1989.

Food and Drug Administration (FDA) 21 CFR Part 1271, a new federal regulation with an anticipated effective date of May 2005, requires human cellular and tissue-based products to be manufactured in compliance with good tissue practices (cGTPs). The Company’s new laboratory processing facility boasts a class 10,000 clean-room and class 100 environments for the processing of cord blood stem cells and other cellular tissues. In addition, the cellular products cryogenic storage area has been designed as a “bunker”, with enhanced provisions for security, building fortification for environmental element protection and back-up systems for operational redundancies.

“Cryo-Cell’s relocation to the new state-of-the-art facility comes at a time of continuing momentum for the Company as reflected in our recent trend of increased revenues, higher margins and solid earnings”, said Mercedes Walton, Chairman and interim CEO. “In yet another industry leading development, we believe that Cryo-Cell is the first private bank to process cord blood in a technologically and operationally advanced cGMP/cGTP-compliant facility. The new facility represents another major milestone towards Cryo-Cell’s vision of innovative, standard-setting industry leadership driven by our commitment to provide expectant families with a high quality, superior-value service for the preservation of their newborn’s cord blood stem cells. We believe that our new facility positions Cryo-Cell well in the market, and ahead of emerging regulation.”

The newly constructed facility, which also houses the Company’s clinical services, marketing and administrative operations, is designed and appointed to accommodate a broad range of market-facing events such as client tours and open houses, as well as clinician and expectant parent educational workshops. Building public awareness for clinicians and families on the significant benefits of umbilical cord blood stem cell preservation continues to be a major initiative for Cryo-Cell.

As part of the relocation, nearly 75,000 client specimens were successfully moved under tightly monitored and elaborately controlled conditions that included police escort. Processing operations continued daily over the course of the move.

The Company’s new address is: 700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL 34677. The business phone number, (813) 749-2100 and business fax, (813) 855-4745, both have changed. The toll-free number, (800) 786-7235 for Clinical Services, remains the same.

About Cryo-Cell International, Inc.
Based in Oldsmar, Florida, Cryo-Cell is the world`s largest U-Cord® stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. Cryo-Cell is accredited by the American Association of Blood Banks (AABB).

Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.Cryo-Cell.com.

Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by any governmental regulations, proceedings or actions, foreign and domestic; any continued or increased losses, or any inability to obtain acceptable financing, where desirable in the future, in connection with our operating or growth plans; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; the effect of any future reduced cash position and future inability to access borrowings; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the move into our new facility or the operation of the facility; any adverse developments impacting our continued relationship with and success of our licensees, foreign affiliates or investments in, or relationships with, foreign companies; any inability to achieve increases in revenue or earnings from umbilical cord blood stem cell storage; any future inability to substantially achieve the objectives expected from the successful implementation of our strategy; any decline in public market interest in the Company’s business sector; any added requirements imposed on us by new laws or SEC regulations and costs thereof; any technological breakthrough or medical breakthrough that would render the Company’s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the potential impact of negative market influences on the Company’s portfolio of cash, cash equivalents and marketable securities; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company’s business operations; any new technology rendering the Company’s patented equipment or business obsolete; any performance failures related to the Company’s equipment or operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; any negative effect from the filed class action shareholder lawsuits; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.
-END-